03451nam 2200469 450 991064038660332120230509123101.09783031189036(electronic bk.)978303118902910.1007/978-3-031-18903-6(MiAaPQ)EBC7169094(Au-PeEL)EBL7169094(OCoLC)1357017136(DE-He213)978-3-031-18903-6(PPN)267811926(EXLCZ)992594565930004120230509d2023 uy 0engurcnu||||||||txtrdacontentcrdamediacrrdacarrierChallenges and opportunities of mRNA vaccines against SARS-CoV-2 a multidisciplinary perspective /Siguna Mueller1st ed. 2023.Cham, Switzerland :Springer,[2023]©20231 online resource (460 pages)Print version: Mueller, Siguna Challenges and Opportunities of MRNA Vaccines Against SARS-CoV-2 Cham : Springer International Publishing AG,c2023 9783031189029 Chapter 1: Introduction -- Part I: Scientifi Underpinnings, early expectations, and emerging challenges from the global inoculation experience -- Chapter 2: Appraisal of Some of the Key Postulates Underlying mRNA Vaccines -- Chapter 3: Relevance for mRNA vaccine safety -- Chapter 4: From Challenges to Opportunities and Open Questions -- Chapter 5: The challenge of evaluating vaccine safety and effectiveness -- Chapter 6: Safeguarding against the analog of antimicrobial-resistance development -- Chapter 7: Scales, pseudoscales, the human factor, and a way forward -- Part II: A deeper dive into mRNA vaccine safety and security, and developments until Delta -- Chapter 8: mRNA Vaccine safety and efficacy - official criteria when AEs are caused by the injection -- Chapter 9: mRNA Covid-19 vaccines best reflect effective pharmaceuticals - basic considerations and LNPs -- Chapter 10: mRNA Covid-19 pharmaceuticals and the spike antigen -- Chapter 11: Other facets of SARS-CoV-2 immunity, the risk of immune tolerance and T cell exhaustion -- Part III: The Omicron variants -- Chapter 12: Omicron -- Chapter 13: Conclusion.This book offers an analytical look at the much debated risks and benefits of the newly developed COVID-19 mRNA-vaccines. As such, it is one of the first books to give a comprehensive overview of mRNA vaccines against COVID-19 and the only one that addresses this topic from a broad multidisciplinary background. It brings together insights from various underlying disciplines on the challenges of developing and evaluating the most suitable vaccines for mass vaccination programs enrolled throughout the world - focusing on safety and efficacy. This book should not be missing on the shelf of any biomedical researcher, epidemiologist, public health professional or clinical researcher interested in SARS-CoV2 or virology and vaccine development in general. .COVID-19 (Disease)PreventionCOVID-19 vaccinesCOVID-19 (Disease)Prevention.COVID-19 vaccines.362.1962414Mueller Siguna1354578MiAaPQMiAaPQMiAaPQ9910640386603321Challenges and Opportunities of mRNA Vaccines Against SARS-CoV-23344795UNINA